Clinical Trials Browser

Fallopian Tube Neoplasms, Ovarian Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Breast Neoplasms, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms, Recurrence

Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Bile Duct Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Ovarian Neoplasms

Clinical Trials

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

BACON

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer

A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Chemotherapy in Advanced Ovarian Cancer With High PARK2 Expression

Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer

To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer

TROY

EZHiSWITCH

Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors

NEOCATS

Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer

Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer

Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

DNPSPIO

Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment